文献速递细胞病理与分子病理

COVID-19疫情对亚太地区细胞病理学实践的影响:一项国际调查

Impact of the COVID-19 pandemic on cytology practice: An international survey in the Asia-Pacific region.
PubMed 文献 · Cancer Cytopathol · 2020-09-15

该研究通过在线问卷对亚太24国167个细胞病理实验室调查2020年2-4月COVID-19对细胞学实践的影响。多数实验室报告限制措施实施、工作流程和工作量受影响,妇科和非妇科标本量显著减少(>10%),但恶性肿瘤率多数无显著变化。

要点

  • 疫情期间多数实验室报告妇科和非妇科细胞学标本量减少>10%。
  • 约半数实验室实施新生物安全协议并改进实验室设施。
  • 多数实验室细胞学恶性肿瘤率与2019年同期相比无显著变化。

核心结论

  • COVID-19大流行导致细胞学检查标本数量显著减少,并需要实施新的生物安全协议。

研究设计与样本

  • 在线问卷调查研究,共167个来自24个亚太国家的细胞病理实验室参与,调查时间为2020年2月至4月。

主要发现

  • 80.8%的实验室报告其城市和/或国家实施了限制医疗服务可及性的措施,83.8%报告其医院实施了此类措施。
  • 54.5%的实验室报告实施了新生物安全协议,47.3%报告改进了实验室设施。
  • 53.3%的实验室报告劳动力重新安排,34.1%报告劳动力重新调配。
  • 82.0%的实验室报告妇科标本量显著减少(>10%),78.4%报告非妇科标本量显著减少(>10%)。
  • 67.7%的实验室报告妇科标本恶性肿瘤率无显著变化,58.7%报告非妇科标本恶性肿瘤率无显著变化。

临床怎么用

  • 细胞病理实验室需建立并标准化生物安全协议以应对公共卫生突发事件。
  • 疫情等限制措施期间应关注细胞学标本量下降对诊断服务的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of the current study was to examine the impact of coronavirus disease 2019 (COVID-19) on various aspects of cytology practice in the Asia-Pacific region. METHODS: An online questionnaire was distributed to cytopathology laboratories in 24 Asia-Pacific countries to explore the impact of restrictive measures on access to health care, use of general and personal protective equipment (PPE), and changes in cytology workflow and workload from February to April 2020. RESULTS: A total of 167 cytopathology laboratories from 24 countries responded to the survey; the majority reported that restrictive measures that limited the accessibility of health care services had been implemented in their cities and/or countries (80.8%) and their hospitals (83.8%). The respondents noted that COVID-19 had an impact on the cytologic workflow as well as the workload. Approximately one-half of the participants reported the implementation of new biosafety protocols (54.5%) as well as improvements in laboratory facilities (47.3%). Rearrangement or redeployment of the workforce was reported in 53.3% and 34.1% of laboratories, respectively. The majority of the respondents reported a significant reduction (>10%) in caseload associated with both gynecological (82.0%) and nongynecological specimens (78.4%). Most laboratories reported no significant change in the malignancy rates of both gynecological (67.7%) and nongynecological specimens (58.7%) compared with the same period in 2019. CONCLUSIONS: The results of the survey demonstrated that the COVID-19 pandemic resulted in a significant reduction in the number of cytology specimens examined along with the need to implement new biosafety protocols. These findings underscore the need for the worldwide standardization of biosafety protocols and cytology practice.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Wang YH, Bychkov A, Chakrabarti I, et al. Impact of the COVID-19 pandemic on cytology practice: An international survey in the Asia-Pacific region. Cancer Cytopathol. 2020. PMID: 32931161. doi:10.1002/cncy.22354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。